BioSpace News Archive

Monogram Orthopaedics Inc. (NASDAQ:MGRM) (“Monogram” or the “Company”), a medical technology company focused on reconstructive joint procedures and surgical robotics, has reported its financial and operational results for the fourth quarter and full year ended December 31, 2023.

SELLAS Life Sciences Group, Inc. announced that it has entered into definitive agreements with two existing institutional investors for the purchase and sale of 13,029,316 shares of its common stock in a registered direct offering and warrants to purchase up to an aggregate of 13,029,316 shares of common stock in a concurrent private placement at a combined purchase price of $1.535 per share and accompanying warrant, priced at-the-market under Nasdaq rules.

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”) announced today the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, REZDIFFRA) for the treatment of NASH/MASH and liver fibrosis.

Cambridge Isotope Laboratories, Inc., the world leader in stable isotope chemistry and the separation of carbon-13, has announced it will be relocating and expanding its corporate headquarters to newly purchased space in Tewksbury, MA, to advance the operations and growth of the company.

Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”) today announced financial results for its fourth quarter and full year ended December 31, 2023.

Pharmascience Canada is proud to announce the launch of pms- METHOTREXATE INJECTION (methotrexate injection) 50 mg/ml, a drug indicated for the treatment of psoriasis, psoriatic arthritis and rheumatoid arthritis in adults aged 18 to 65 with severe disabling conditions, when other treatments do not work.

Dr. Ameer Hassan, a distinguished figure in the realm of neurology and neuroendovascular medicine, proudly announces the establishment of the Dr. Ameer Hassan Scholarship for Medical Students.

Optinose (NASDAQ:OPTN) today announced the U.S. Food and Drug Administration (FDA) has approved XHANCE® (fluticasone propionate) nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.